All News

3 January 2008

ImmunoGen, Inc. Expands Pipeline of Targeted Anticancer CompoundsAntibodies

3 January 2008

Expanded Labeling for MabCampath(R) in EuropeAntibodies

30 December 2007

MorphoSys Files Clinical Trial Application to Initiate First Phase 1 Clinical Study of its MOR103 ProgramAntibodies

22 December 2007

Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer’s DiseaseAntibodies

21 December 2007

Fresenius Biotech applies for the marketing authorization of the trifunctional antibody Removab (R) for the treatment of malignant ascitesAntibodies

21 December 2007

Centocor, Schering-Plough Revise Agreement Covering REMICADE, GolimumabAntibodies

20 December 2007

Ablinx Extends Agreement With WyethAntibodies

20 December 2007

Abbott’s HUMIRA (R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque PsoriasisAntibodies

20 December 2007

R1507 antibody to enter Phase II study to treat sarcomaAntibodies

20 December 2007

Human Genome Sciences initiates second randomized Phase 2 trial of HGS- ETR 1 in combination with chemotherapyAntibodies

19 December 2007

Avastin approved in Europe for first-line treatment of patients with advanced kidney cancerAntibodies

17 December 2007

Ablynx Reports Positive Phase I Results for Its Anti-Thrombotic Nanobody(R), ALX-0081Antibodies

17 December 2007

Auxilium Pharmaceuticals, Inc. Completes Enrollment in Two Phase III Clinical Trials of XIAFLEX(TM) for Dupuytren’s ContractureAntibodies

14 December 2007

Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor TherapyAntibodies

13 December 2007

WILEX announces positive result of the interim analysis for futility of its Phase III ARISER trial with RENCAREX(R)Antibodies

13 December 2007

Genmab initiates Ofatumumab Phase II study in diffuse large b-cell lymphomaAntibodies

13 December 2007

Genmab announces details of planned Ofatumumab Phase II study in multiple sclerosisAntibodies

13 December 2007

Merck Announces Initiation of Phase II/III Clinical Trial of Atacicept in Lupus NephritisAntibodies

11 December 2007

Fourth Genmab Antibody Developed Under Roche Collaboration to Enter ClinicAntibodies

11 December 2007

ThromboGenics Presents Results of the Phase I Trial of TB-402 at thePrestigious American Society of Hematology Annual MeetingAntibodies

10 December 2007

Seattle Genetics Reports Multiple Complete Remissions With SGN-33 in Acute Myeloid Leukemia at ASHAntibodies

10 December 2007

GlaxoSmithKline and OncoMed Pharmaceuticals Form Strategic Alliance to Develop Cancer Stem Cell Antibody TherapeuticsAntibodies

10 December 2007

Biolex Researchers Present Results of Anti-CD20 Antibody With Optimized Glycosylation at ASH ConferenceAntibodies

10 December 2007

Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)Antibodies

10 December 2007

Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic MelanomaAntibodies

10 December 2007

Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin’s LymphomaAntibodies

10 December 2007

Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary EndpointsAntibodies

10 December 2007

Ablynx announces extension of Nanobody (R) drug discovery and development allianceAntibodies

10 December 2007

PDL BioPharma Presents Data on Novel Monoclonal Antibody for Multiple Myeloma at the 2007 American Society of Hematology Annual MeetingAntibodies

10 December 2007

MorphoSys Broadens Scope of Collaboration with GeneFrontierAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Mesothelin-Targeted Immunotherapy Pipeline Review

TL1A Inhibitor Pipeline Review

PSMA-Targeted Therapy Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Bispecific Antibodies for Immuno-Oncology & Other Diseases